直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
  • 新闻
  • 飞翰事实
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • 慈善性法律援助
  • 管理层
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

James R. Barney

USPTO Upholds i4i Patent in Dispute with Microsoft

July 27, 2010

Law360

The U.S. Patent and Trademark Office (USPTO) has upheld the i4i LP patent at the center of a lawsuit with Microsoft Corp., finding all the challenged claims patentable. “The USPTO issued a re-examination certificate Tuesday confirming the patentability of U.S. Patent Number 5,787,449, marking an end to the re-examination process Microsoft initiated after being sued by i4i in 2007,” i4i said. Toronto-based i4i sued Microsoft in the U.S. District Court for the Eastern District of Texas in March 2007, claiming that the defendant incorporated technology claimed in the '449 patent into its Word software. On Aug. 11, after a jury trial, Judge Leonard Davis awarded i4i $290 million in damages and banned sales of the allegedly infringing Word software. Finnegan represented i4i in the courts.

Related News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Commentary

Quince Aims to Have ‘Dupe’ Evidence Shape Ugg Shoe Patent Trial

May 26, 2026

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Press Release

Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination

May 11, 2026

Commentary

ITC Bars Import of Innoscience Chips Made Before Redesign

May 8, 2026

Commentary

How Litigation Funding Disclosure Could Affect ITC Cases

May 7 , 2026

Award/Ranking

Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey

May 7, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP